Login
Companies $MGNX
$2.14 -$0.03 (1.38%) After hours
MACROGENICS INC logo

MACROGENICS INC

macrogenics.com

What Do They Do?

Partners with biopharmaceutical companies to develop and license antibody-based cancer drug candidates for patients; also develops its own cancer treatments and provides drug manufacturing services.

How Do They Make Money?

Biopharmaceutical partners pay upfront license fees, option and milestone payments, and royalties when licensed products sell; they also pay for research and manufacturing work as it is performed.

revenue
SegmentShareRevenue
Collaborative and other agreements
58%
FY2022: 79%
Contract manufacturing
Recurring

35%
FY2022: 9.2%
Product sales, net
0.0%
FY2022: 11%
Royalty revenue
Licensed
6.5%

Who Are Their Customers?

Biopharmaceutical collaborators license product candidates and work with MacroGenics on development; collaborators and other third parties use its contract development and manufacturing services.

Do Revenues Turn Into Profits?

No. It lost $74.6M in FY2025.

Operating income, FY2025
−49% of revenue
▲ +34% (Loss) vs FY2024 (−$110.6M, −74%)
Net income, FY2025
−50% of revenue
▼ −11% (Loss) vs FY2024 (−$67M, −45%)
Free cash flow, FY2025
−55% of revenue
▼ −15% (Loss) vs FY2024 (−$72.1M, −48%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▼ −65%
vs $53M in Q3 FY2025
Net income
▼ Turned to a loss
vs $16.8M in Q3 FY2025
Collaborative and other agreements share of revenue vs 93.7% in Q3 FY2025
  • Jun 30, 2026 Sold its GMP manufacturing and contract manufacturing business Bora paid $122.5 million and assumed responsibility for the operations; MacroGenics retained a supply agreement for its pipeline needs.

Growing. Revenue grew 93% in 4 years, from $77.4M in FY2021 to $149.5M in FY2025, about 18% a year.

MARGENZA commercialization The earlier report described MacroGenics marketing MARGENZA with a partner; the latest says it sold global rights to TerSera and may receive sales milestone payments.

Revenue over time
Collaborative and other agreements Contract manufacturing Product sales, net Royalty revenue Revenue from government agreements
$200M$100M$0

Who Do They Compete With?

Competes with Akeso, AstraZeneca, Jiangsu Alphamab Biopharmaceuticals, Abbvie, BeOne Medicines, BioNTech, Duality Biotherapeutics, Genmab, GSK, Hansoh Pharmaceutical, Innovent Biologics, MediLink Therapeutics, Merck &, Pfizer, Amgen, F. Hoffmann-La Roche, Genentech, Janux Therapeutics, Johnson & Johnson Services, and Regeneron Pharmaceuticals

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support